Citations (111)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Cengiz Cengisiz & Emre Misir. (2023) Dimensional characteristics of persistent negative symptoms in schizophrenia and their relationships with schizotypy in first-degree relatives. Nordic Journal of Psychiatry 77:8, pages 737-746.
Read now
Read now
Jonas Montvidas, Virginija Adomaitienė, Darius Leskauskas & Sonia Dollfus. (2021) Validation of the lithuanian version of the self-evaluation of negative symptoms scale (SNS). Nordic Journal of Psychiatry 75:5, pages 351-355.
Read now
Read now
Christoph U Correll & Nina R Schooler. (2020) Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatric Disease and Treatment 16, pages 519-534.
Read now
Read now
Jaśmina Arabska, Aleksandra Margulska, Dominik Strzelecki & Adam Wysokiński. (2019) Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia?. Nordic Journal of Psychiatry 73:8, pages 515-521.
Read now
Read now
Aubrey M. Moe & Nicholas J.K. Breitborde. (2019) Psychosis in Emerging Adulthood: Phenomenological, Diagnostic, and Clinical Considerations. Evidence-Based Practice in Child and Adolescent Mental Health 4:2, pages 141-156.
Read now
Read now
Juliet Silberstein & Philip D. Harvey. (2019) Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes. Cognitive Neuropsychiatry 24:1, pages 28-39.
Read now
Read now
Chiraz Azaiez, Aurélie Millier, Christophe Lançon, Emilie Clay, Pascal Auquier, Pierre-Michel Llorca & Mondher Toumi. (2018) Health related quality of life in patients having schizophrenia negative symptoms – a systematic review. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Jiyang Han, Yan Li & Xumei Wang. (2017) Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2935-2943.
Read now
Read now
Mirna Sisek-Šprem, Aida Križaj, Vlado Jukić, Milan Milošević, Zrinka Petrović & Miroslav Herceg. (2015) Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression. Nordic Journal of Psychiatry 69:2, pages 102-109.
Read now
Read now
Pierre Chue & Justine K Lalonde. (2014) Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment 10, pages 777-789.
Read now
Read now
Freddy Sarin & Lennart Wallin. (2014) Cognitive model and cognitive behavior therapy for schizophrenia: An overview. Nordic Journal of Psychiatry 68:3, pages 145-153.
Read now
Read now
Cindy L Hovington & Martin Lepage. (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Review of Neurotherapeutics 12:1, pages 53-69.
Read now
Read now
Articles from other publishers (99)
Rasmus Handest, Ida-Marie Molstrom, Mads Gram Henriksen, Carsten Hjorthøj & Julie Nordgaard. (2023) A Systematic Review and Meta-Analysis of the Association Between Psychopathology and Social Functioning in Schizophrenia. Schizophrenia Bulletin 49:6, pages 1470-1485.
Crossref
Crossref
Dylan Flaws, Sue Patterson, Todd Bagshaw, Kym Boon, Justin Kenardy, David Sellers & Oystein Tronstad. (2023) Caring for critically ill patients with a mental illness: A discursive paper providing an overview and case exploration of the delivery of intensive care to people with psychiatric comorbidity. Nursing Open 10:11, pages 7106-7117.
Crossref
Crossref
Renliang Cai, Chengbing Huang, Longyan Ni, Zihan Liu, Sijie Zhang, Yufeng Qiu, Jianing Hu, Ju Gao, Miao Yu, Xiaowei Tang, Chao Zhou, Xiaobin Zhang, Xiangrong Zhang & Xinyu Fang. (2023) The motivation and pleasure deficits but not expressivity affects social functioning through cognitive function in male patients with schizophrenia: A structural equation model. Asian Journal of Psychiatry 85, pages 103616.
Crossref
Crossref
Sofia Pappa, Arturas Kalniunas & Jose Maret. (2023) Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up. Frontiers in Psychiatry 14.
Crossref
Crossref
Ian M. Raugh, Lauren Luther, Lisa A. Bartolomeo, Tina Gupta, Ivanka Ristanovic, Andrea Pelletier-Baldelli, Vijay A. Mittal, Elaine F. Walker & Gregory P. Strauss. (2023) Negative Symptom Inventory-Self-Report (NSI-SR): Initial development and validation. Schizophrenia Research 256, pages 79-87.
Crossref
Crossref
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, Heather Dworak, Courtney Zeni & Kenneth Koblan. (2023) Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience.
Crossref
Crossref
Judith M. Gault, Patrick Hosokawa, Daniel Kramer, Elyn R. Saks, Paul S. Appelbaum, John A. Thompson, Ann Olincy, Nicola Cascella, Akira Sawa, Wayne Goodman, Nidal Moukaddam, Sameer A. Sheth, William S. Anderson & Rachel A. Davis. (2023) Postsurgical morbidity and mortality favorably informs deep brain stimulation for new indications including schizophrenia and schizoaffective disorder. Frontiers in Surgery 10.
Crossref
Crossref
Samad Fereidooni, Amir Hoshang Mehryar, Hajjotollah Javidi & Ramin Afshari. (2023) Effect of Family Psychological Education Program on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Controlled Trial. Jundishapur Journal of Chronic Disease Care 12:1.
Crossref
Crossref
Bianca Daniela Crecan-Suciu & Ramona Păunescu. 2023. Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives. Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives.
Jacopo Lisoni, Giulia Baldacci, Gabriele Nibbio, Andrea Zucchetti, Elena Butti Lemmi Gigli, Arianna Savorelli, Michele Facchi, Paola Miotto, Giacomo Deste, Stefano Barlati & Antonio Vita. (2022) Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with schizophrenia: Results of a randomized double-blind sham-controlled trial. Journal of Psychiatric Research 155, pages 430-442.
Crossref
Crossref
Tingting Zhu, Zixu Wang, Chao Zhou, Xinyu Fang, Chengbing Huang, Chunming Xie, Honglin Ge, Zheng Yan, Xiangrong Zhang & Jiu Chen. (2022) Meta-analysis of structural and functional brain abnormalities in schizophrenia with persistent negative symptoms using activation likelihood estimation. Frontiers in Psychiatry 13.
Crossref
Crossref
Ashleigh Grindey & Tim Bradshaw. (2022) Do different adverse childhood experiences lead to specific symptoms of psychosis in adulthood? A systematic review of the current literature. International Journal of Mental Health Nursing 31:4, pages 868-887.
Crossref
Crossref
Miranda Bridgwater, Peter Bachman, Brenden Tervo-Clemmens, Gretchen Haas, Rebecca Hayes, Beatriz Luna, Dean F. Salisbury & Maria Jalbrzikowski. (2020) Developmental influences on symptom expression in antipsychotic-naïve first-episode psychosis. Psychological Medicine 52:9, pages 1698-1709.
Crossref
Crossref
Katie M. Lavigne, Delphine Raucher-Chéné, Michael D. Bodnar, Carolina Makowski, Ridha Joober, Ashok Malla, Alan C. Evans & Martin Lepage. (2022) Medial temporal lobe and basal ganglia volume trajectories in persistent negative symptoms following a first episode of psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 117, pages 110551.
Crossref
Crossref
Onur AĞDANLI, Ahmet TOPUZOGLU, Nuri KARABAY & Köksal ALPTEKİN. (2022) Corpus Callosum Volume in Patients with First-Episode Psychosis. Clinical and Experimental Health Sciences 12:2, pages 331-336.
Crossref
Crossref
Mihaela Fadgyas Stanculete & Octavia Capatina. 2022. Psychosis - Phenomenology, Psychopathology and Pathophysiology. Psychosis - Phenomenology, Psychopathology and Pathophysiology.
Pasquale Pezzella, Giulia Maria Giordano & Silvana Galderisi. 2022. Prevention in Mental Health. Prevention in Mental Health
335
369
.
Maris Taube. (2021) Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery. Frontiers in Psychiatry 12.
Crossref
Crossref
Karlijn S. F. M. Hermans, Inez Myin-Germeys, Charlotte Gayer-Anderson, Matthew J. Kempton, Lucia Valmaggia, Philip McGuire, Robin M. Murray, Philippa Garety, Til Wykes, Craig Morgan, Zuzana Kasanova & Ulrich Reininghaus. (2020) Elucidating negative symptoms in the daily life of individuals in the early stages of psychosis. Psychological Medicine 51:15, pages 2599-2609.
Crossref
Crossref
Qiongqiong Wu, Xiaoyi Wang, Ying Wang, Yu-Jun Long, Jing-Ping Zhao & Ren-Rong Wu. (2021) Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia. Neuroscience Bulletin 37:11, pages 1609-1624.
Crossref
Crossref
Youssuf Saleh, Isaac Jarratt-Barnham, Emilio Fernandez-Egea & Masud Husain. (2021) Mechanisms Underlying Motivational Dysfunction in Schizophrenia. Frontiers in Behavioral Neuroscience 15.
Crossref
Crossref
Hua Ye, Andrew Zalesky, Jinglei Lv, Samantha M Loi, Suheyla Cetin-Karayumak, Yogesh Rathi, Ye Tian, Christos Pantelis & Maria A Di Biase. (2021) Network Analysis of Symptom Comorbidity in Schizophrenia: Relationship to Illness Course and Brain White Matter Microstructure. Schizophrenia Bulletin 47:4, pages 1156-1167.
Crossref
Crossref
Philipp Berger, Florian Bitsch & Irina Falkenberg. (2021) Humor in Psychiatry: Lessons From Neuroscience, Psychopathology, and Treatment Research. Frontiers in Psychiatry 12.
Crossref
Crossref
Sergio Hidalgo, Jorge M. Campusano & James J. L. Hodge. (2021) Assessing olfactory, memory, social and circadian phenotypes associated with schizophrenia in a genetic model based on Rim. Translational Psychiatry 11:1.
Crossref
Crossref
Ehud Mekori-Domachevsky, Michal Taler, Ronnie Weinberger, Yael Guri, Shira Dar, Shachar Shani, Idit Dekel, Abraham Weizman & Doron Gothelf. (2021) Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome – Clinical and scientific implications. Schizophrenia Research 231, pages 164-169.
Crossref
Crossref
M. V. Assanovich & V. A. Karpiuk. (2021) Psychometric properties and diagnostic criteria of Scale for the assessment of negative symptoms (SANS) in schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY:1, pages 33-41.
Crossref
Crossref
E. M. M. van Bussel, N. H. M. Nguyen, A. I. Wierdsma, B. C. van Aken, I. E. M. G. Willems & C. L. Mulder. (2021) Adult Attachment and Personal, Social, and Symptomatic Recovery From Psychosis: Systematic Review and Meta-Analysis. Frontiers in Psychiatry 12.
Crossref
Crossref
S. Galderisi, A. Mucci, S. Dollfus, M. Nordentoft, P. Falkai, S. Kaiser, G. M. Giordano, A. Vandevelde, M. Ø. Nielsen, L. B. Glenthøj, M. Sabé, P. Pezzella, I. Bitter & W. Gaebel. (2021) EPA guidance on assessment of negative symptoms in schizophrenia. European Psychiatry 64:1.
Crossref
Crossref
L. Roebroek, J. Bruins, D. Roe, P. Delespaul, S. de Jong, A. Boonstra, E. Visser & S. Castelein. (2021) Care needs and care consumption in psychosis: a 4-year longitudinal analysis of guideline concordant care. Epidemiology and Psychiatric Sciences 30.
Crossref
Crossref
Kyungmi Park & Moonhee Gang. (2020) Nurses' Assessment of Sedation of Patients With Mental Illness: Scale Development and Validation. Journal of Psychosocial Nursing and Mental Health Services 58:12, pages 22-31.
Crossref
Crossref
Xiao Wang, Fengmei Lu, Xujun Duan, Shaoqiang Han, Xiaonan Guo, Mi Yang, Yan Zhang, Jinming Xiao, Wei Sheng, Jingping Zhao & Huafu Chen. (2020) Frontal white matter abnormalities reveal the pathological basis underlying negative symptoms in antipsychotic-naïve, first-episode patients with adolescent-onset schizophrenia: Evidence from multimodal brain imaging. Schizophrenia Research 222, pages 258-266.
Crossref
Crossref
Gabriele Cipriani, Sabrina Danti, Angelo Nuti, Mario Di Fiorino & Davide M. Cammisuli. (2020) Is that schizophrenia or frontotemporal dementia? Supporting clinicians in making the right diagnosis. Acta Neurologica Belgica 120:4, pages 799-804.
Crossref
Crossref
Tesfa Dejenie Habtewold, Lyan H. Rodijk, Edith J. Liemburg, Grigory Sidorenkov, H. Marike Boezen, Richard Bruggeman & Behrooz Z. Alizadeh. (2020) A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits. Translational Psychiatry 10:1.
Crossref
Crossref
Takeshi Shimada, Shoko Ito, Aya Makabe, Ayumi Yamanushi, Ami Takenaka, Kojiro Kawano & Masayoshi Kobayashi. (2020) Aerobic exercise and cognitive functioning in schizophrenia: Results of a 1-year follow-up from a randomized controlled trial. Psychiatry Research 286, pages 112854.
Crossref
Crossref
Corrado Sandini, Stephan Eliez, Maude Schneider & Marco Armando. 2020. Risk Factors for Psychosis. Risk Factors for Psychosis
143
164
.
Annika Clamor, Inga Frantz & Tania M. Lincoln. 2020. Klinische Psychologie & Psychotherapie. Klinische Psychologie & Psychotherapie
947
1003
.
Jelle Sjoerd Vogel, Mark van der Gaag, Christien Slofstra, Henderikus Knegtering, Jojanneke Bruins & Stynke Castelein. (2019) The effect of mind-body and aerobic exercise on negative symptoms in schizophrenia: A meta-analysis. Psychiatry Research 279, pages 295-305.
Crossref
Crossref
Daina Crafa, Joanna Q. Liu & Mathieu B. Brodeur. (2019) Social Values and Determinants of Cultural Fit in Quebec: The Roles of Ancestry, Linguistic Group, and Mental Health Status. Frontiers in Psychology 10.
Crossref
Crossref
Travis A. Wearne & Jennifer L. Cornish. (2018) A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. Frontiers in Psychiatry 9.
Crossref
Crossref
Monica F. Tomlinson & Joshua D. Wright. (2018) Identifying the “Therapy Targets” for Treating the Negative Symptoms of Psychosis Using Cognitive Behavioral Therapy. Journal of Cognitive Psychotherapy 32:3, pages 203-220.
Crossref
Crossref
Sara Mubeen, Hafiz Muhammad Mudassar Aslam, Muhammad Tamour Danish, Muhammad Imran, Aamira Hashmi & Muhammad Hashim Raza. (2018) Effect of Risperidone with Ondansetron to Control the Negative and Depressive Symptoms in Schizophrenia. Advances in Science, Technology and Engineering Systems Journal 3:3, pages 100-103.
Crossref
Crossref
Paul R L Matthews, Jamie Horder & Michael Pearce. (2018) Selective noradrenaline reuptake inhibitors for schizophrenia. Cochrane Database of Systematic Reviews 2018:1.
Crossref
Crossref
Marc Fakhoury. (2017) The habenula in psychiatric disorders: More than three decades of translational investigation. Neuroscience & Biobehavioral Reviews 83, pages 721-735.
Crossref
Crossref
Seiji Humphries, Robert King, Michael P Dunne & Cat Huu Nguyen. (2017) Early psychosis in central Vietnam: A longitudinal study of short-term functional outcomes and their predictors. International Journal of Social Psychiatry 63:7, pages 602-613.
Crossref
Crossref
Gisela Mezquida, Bibiana Cabrera, Miquel Bioque, Silvia Amoretti, Antonio Lobo, Ana González-Pinto, Ana Espliego, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Daniel Bergé, Maria J. Escartí, Ángela Ibañez, Rafael Penadés, Ana M. Sánchez-Torres, Miguel Bernardo, Ana Meseguer, Emilio Fernandez-Egea, Jorge Vidal, Mara Parellada, Anna Alonso, Mireia Rabella, Patricia Vega, Amaia Ugarte, Helena Andrés-Bergareche, Fabiola Modrego, Julio Sanjuan, Eduardo J. Aguilar, Antoni Bulbena, Anna Mané, Marina Garriga, Ivette Morilla, Immaculada Baeza, Elena de la Serna, Fernando Contreras, Auria Albacete, Julio Bobes, M. Paz García-Portilla, Miguel Gutiérrez, Rafael Segarra, Isabel Morales-Muñoz, Roberto Rodriguez-Jimenez, Anna Butjosa, Judith Usall, Salvador Sarró, Ramón Landin-Romero, Jerónimo Saiz & Vicent Balanzá-Martínez. (2017) The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research 189, pages 84-90.
Crossref
Crossref
Armida Mucci, Eleonora Merlotti, Alp Üçok, André Aleman & Silvana Galderisi. (2017) Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. Schizophrenia Research 186, pages 19-28.
Crossref
Crossref
Timothy P. Rutkowski, Jason P. Schroeder, Georgette M. Gafford, Stephen T. Warren, David Weinshenker, Tamara Caspary & Jennifer G. Mulle. (2017) Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders. Journal of Neuroscience Research 95:5, pages 1144-1160.
Crossref
Crossref
Xing Meng, Rongtao Jiang, Dongdong Lin, Juan Bustillo, Thomas Jones, Jiayu Chen, Qingbao Yu, Yuhui Du, Yu Zhang, Tianzi Jiang, Jing Sui & Vince D. Calhoun. (2017) Predicting individualized clinical measures by a generalized prediction framework and multimodal fusion of MRI data. NeuroImage 145, pages 218-229.
Crossref
Crossref
Manli Huang, Yi Huang, Liang Yu, Jianbo Hu, Jinkai Chen, Pingbo Jin, Weijuan Xu, Ning Wei, Shaohua Hu, Hongli Qi & Yi Xu. (2016) Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry 16:1.
Crossref
Crossref
Anna Butjosa, Juana Gómez-Benito, Elena Huerta-Ramos, Núria Del cacho, Ana Barajas, Iris Baños, Judith Usall, Montserrat Dolz, Bernardo Sánchez, Janina Carlson, Josep Maria Haro & Susana Ochoa. (2016) Incidence of stressful life events and influence of sociodemographic and clinical variables on the onset of first-episode psychosis. Psychiatry Research 245, pages 108-115.
Crossref
Crossref
Marc Fakhoury. (2016) Could cannabidiol be used as an alternative to antipsychotics?. Journal of Psychiatric Research 80, pages 14-21.
Crossref
Crossref
Adrianna Mendrek & Adham Mancini-Marïe. (2016) Sex/gender differences in the brain and cognition in schizophrenia. Neuroscience & Biobehavioral Reviews 67, pages 57-78.
Crossref
Crossref
Wolfram an der Heiden, Anne Leber & Heinz Häfner. (2016) Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 266:5, pages 387-396.
Crossref
Crossref
Brioney Gee, Jo Hodgekins, David Fowler, Max Marshall, Linda Everard, Helen Lester, Peter B. Jones, Tim Amos, Swaran P. Singh, Vimal Sharma, Nick Freemantle & Max Birchwood. (2016) The course of negative symptom in first episode psychosis and the relationship with social recovery. Schizophrenia Research 174:1-3, pages 165-171.
Crossref
Crossref
Henriëtte D. Heering & Neeltje E.M. van Haren. (2016) Social functioning in patients with a psychotic disorder and first rank symptoms. Psychiatry Research 237, pages 147-152.
Crossref
Crossref
Negar Iranpour, Atefeh Zandifar, Mehdi Farokhnia, Amirhossein Goguol, Habibeh Yekehtaz, Mohammad-Reza Khodaie-Ardakani, Bahman Salehi, Sophia Esalatmanesh, Atefeh Zeionoddini, Payam Mohammadinejad, Arefeh Zeinoddini & Shahin Akhondzadeh. (2016) The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Human Psychopharmacology: Clinical and Experimental 31:2, pages 103-112.
Crossref
Crossref
Monika Szkultecka-Dębek, Jacek Walczak, Joanna Augustyńska, Katarzyna Miernik, Jarosław Stelmachowski, Izabela Pieniążek, Grzegorz Obrzut, Angelika Pogroszewska, Gabrijela Paulić, Marić Damir, Siniša Antolić, Rok Tavčar, Andra Indrikson, Kaire Aadamsoo, Slobodan Jankovic, Attila J Pulay, József Rimay, Márton Varga, Ivana Sulkova & Petra Veržun. (2015) Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review. Clinical Practice & Epidemiology in Mental Health 11:1, pages 158-165.
Crossref
Crossref
John Lyne, Laoise Renwick, Brian O'Donoghue, Anthony Kinsella, Kevin Malone, Niall Turner, Eadbhard O'Callaghan & Mary Clarke. (2015) Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. Psychiatry Research 228:3, pages 347-354.
Crossref
Crossref
Geneviève Bourdeau, Tania Lecomte & Paul H. Lysaker. (2015) Stages of recovery in early psychosis: Associations with symptoms, function, and narrative development. Psychology and Psychotherapy: Theory, Research and Practice 88:2, pages 127-142.
Crossref
Crossref
Maren Klug, Rachel Hill & Maarten Van den Buuse. 2015. Psychiatry and Neuroscience Update. Psychiatry and Neuroscience Update
335
351
.
Cristiana Montemagni, Filomena Castagna, Barbara Crivelli, Giampiero De Marzi, Tiziana Frieri, Antonio Macrì & Paola Rocca. (2014) Relative contributions of negative symptoms, insight, and coping strategies to quality of life in stable schizophrenia. Psychiatry Research 220:1-2, pages 102-111.
Crossref
Crossref
Philip Gerretsen, Eric Plitman, Tarek K. Rajji & Ariel Graff-Guerrero. (2014) The effects of aging on insight into illness in schizophrenia: a review. International Journal of Geriatric Psychiatry 29:11, pages 1145-1161.
Crossref
Crossref
Kenneth L. Subotnik, Joseph Ventura, Denise Gretchen-Doorly, Gerhard S. Hellemann, Elisha R. Agee, Laurie R. Casaus, John S. Luo, Kathleen F. Villa & Keith H. Nuechterlein. (2014) The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia. Schizophrenia Research 159:1, pages 95-100.
Crossref
Crossref
Heinz Häfner. (2014) The Concept of Schizophrenia: From Unity to Diversity. Advances in Psychiatry 2014, pages 1-39.
Crossref
Crossref
Daryl E. Fujii & Iqbal Ahmed. (2014) Psychotic Disorder Caused by Traumatic Brain Injury. Psychiatric Clinics of North America 37:1, pages 113-124.
Crossref
Crossref
Jihun Hamm, Amy Pinkham, Ruben C. Gur, Ragini Verma & Christian G. Kohler. (2014) Dimensional Information-Theoretic Measurement of Facial Emotion Expressions in Schizophrenia. Schizophrenia Research and Treatment 2014, pages 1-10.
Crossref
Crossref
Maude Schneider, Martial Van der Linden, Sarah Menghetti, Bronwyn Glaser, Martin Debbané & Stephan Eliez. (2014) Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome. Journal of Psychiatric Research 48:1, pages 86-93.
Crossref
Crossref
Hamish J. McLeod, Andrew Gumley & Matthias Schwannauer. 2014. Social Cognition and Metacognition in Schizophrenia. Social Cognition and Metacognition in Schizophrenia
115
135
.
Maike Engel, Anja Fritzsche & Tania M. Lincoln. (2013) Anticipatory pleasure and approach motivation in schizophrenia-like negative symptoms. Psychiatry Research 210:2, pages 422-426.
Crossref
Crossref
Kim Hinkelmann, Alexander Yassouridis, Michael Kellner, Holger Jahn, Klaus Wiedemann & Thomas J. Raedler. (2013) No Effects of Antidepressants on Negative Symptoms in Schizophrenia. Journal of Clinical Psychopharmacology 33:5, pages 686-690.
Crossref
Crossref
Anton B.P. Staring, Mary-Ann B. ter Huurne & Mark van der Gaag. (2013) Cognitive Behavioral Therapy for negative symptoms (CBT-n) in psychotic disorders: A pilot study. Journal of Behavior Therapy and Experimental Psychiatry 44:3, pages 300-306.
Crossref
Crossref
Unni Bratlien, Merete Øie, Lars Lien, Ingrid Agartz, Kristin Lie Romm, Anja Vaskinn, Torill Ueland, Ole A. Andreassen & Ingrid Melle. (2013) Social dysfunction in first-episode psychosis and relations to neurocognition, duration of untreated psychosis and clinical symptoms. Psychiatry Research 207:1-2, pages 33-39.
Crossref
Crossref
Leonardo Cortese, Rodrigo A Bressan, David J Castle & Sergey N Mosolov. (2013) Management of schizophrenia: clinical experience with asenapine. Journal of Psychopharmacology 27:4_suppl, pages 14-22.
Crossref
Crossref
Alejandra Caqueo-Urízar, José Gutiérrez-Maldonado, Marta Ferrer-García, Alfonso Urzúa Morales & Paula Fernández-Dávila. (2011) Typology of schizophrenic symptoms and quality of life in patients and their main caregivers in northern Chile. International Journal of Social Psychiatry 59:1, pages 93-100.
Crossref
Crossref
Maike M. Hartmann, Anja Fritzsche & Tania M. Lincoln. (2013) The extent and origin of discordance between self- and observer-rated depression in patients with psychosis. Psychiatry Research 205:3, pages 247-252.
Crossref
Crossref
Jing Sui, Hao He, Godfrey D. Pearlson, Tülay Adali, Kent A. Kiehl, Qingbao Yu, Vince P. Clark, Eduardo Castro, Tonya White, Bryon A. Mueller, Beng C. Ho, Nancy C. Andreasen & Vince D. Calhoun. (2013) Three-way (N-way) fusion of brain imaging data based on mCCA+jICA and its application to discriminating schizophrenia. NeuroImage 66, pages 119-132.
Crossref
Crossref
Carl I. Cohen, Navin Natarajan, Marie Araujo & Dishal Solanki. (2013) Prevalence of Negative Symptoms and Associated Factors in Older Adults With Schizophrenia Spectrum Disorder. The American Journal of Geriatric Psychiatry 21:2, pages 100-107.
Crossref
Crossref
Vivek Bambole, Nilesh Shah, Shushma Sonavane, Megan Johnston & Amresh Shrivastava. (2013) Study of negatives symptoms in first episode schizophrenia. Open Journal of Psychiatry 03:03, pages 323-328.
Crossref
Crossref
Leslie CitromeLeslie Citrome. 2013. Handbook of Treatment-resistant Schizophrenia. Handbook of Treatment-resistant Schizophrenia
37
56
.
Cindy L Hovington, Michael Bodnar, Ridha Joober, Ashok K Malla & Martin Lepage. (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12:1.
Crossref
Crossref
Piotr Świtaj, Marta Anczewska, Anna Chrostek, Carla Sabariego, Alarcos Cieza, Jerome Bickenbach & Somnath Chatterji. (2012) Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. BMC Psychiatry 12:1.
Crossref
Crossref
Nynke Boonstra, Rianne Klaassen, Sjoerd Sytema, Max Marshall, Lieuwe De Haan, Lex Wunderink & Durk Wiersma. (2012) Duration of untreated psychosis and negative symptoms — A systematic review and meta-analysis of individual patient data. Schizophrenia Research 142:1-3, pages 12-19.
Crossref
Crossref
Marita Pruessner, Srividya N. Iyer, Kia Faridi, Ridha Joober & Ashok K. Malla. (2012) Estrés y factores protectores en individuos en riesgo ultra-alto de psicosis, pacientes con un primer episodio de psicosis e individuos de control sanos. Psiquiatría Biológica 19, pages 6-14.
Crossref
Crossref
Paul Matthews & Jamie Horder. (2012) Selective noradrenaline reuptake inhibitors for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Yanet Quijada, Jorge L. Tizón, Jordi Artigue, Thomas R. Kwapil & Neus Barrantes-Vidal. (2012) Attachment style predicts 6-month improvement in psychoticism in persons with at-risk mental states for psychosis. Early Intervention in Psychiatry 6:4, pages 442-449.
Crossref
Crossref
Alejandra Caqueo-Urízar, José Gutiérrez-Maldonado, Marta Ferrer-García & Paula Fernández-Dávila. (2012) Calidad de vida en pacientes con esquizofrenia de ascendencia étnica aymara en el norte de Chile. Revista de Psiquiatría y Salud Mental 5:2, pages 121-126.
Crossref
Crossref
John Lyne, Brian O'Donoghue, Elizabeth Owens, Laoise Renwick, Kevin Madigan, Anthony Kinsella, Mary Clarke, Niall Turner & Eadbhard O'Callaghan. (2012) Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophrenia Research 135:1-3, pages 128-133.
Crossref
Crossref
Deborah J. Kayman & Marjorie F. Goldstein. (2012) Cognitive Deficits in Schizophrenia. Current Translational Geriatrics and Experimental Gerontology Reports 1:1, pages 45-52.
Crossref
Crossref
Xiao Shifu, Xue Haibo, Li Guanjun, Yuan Chengmei, Li Xia, Chen Chao, Helen Zong Ying Wu, Philip Mitchell & Zhang Mingyuan. (2012) Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. Australian & New Zealand Journal of Psychiatry 46:2, pages 153-160.
Crossref
Crossref
C. Raymond LakeC. Raymond Lake. 2012. Schizophrenia Is a Misdiagnosis. Schizophrenia Is a Misdiagnosis
241
269
.
S. Klingberg, W. Wolwer, C. Engel, A. Wittorf, J. Herrlich, C. Meisner, G. Buchkremer & G. Wiedemann. (2011) Negative Symptoms of Schizophrenia as Primary Target of Cognitive Behavioral Therapy: Results of the Randomized Clinical TONES Study. Schizophrenia Bulletin 37:suppl 2, pages S98-S110.
Crossref
Crossref
T. M. Lincoln, S. Mehl, M.-L. Kesting & W. Rief. (2011) Negative Symptoms and Social Cognition: Identifying Targets for Psychological Interventions. Schizophrenia Bulletin 37:suppl 2, pages S23-S32.
Crossref
Crossref
Shi-Fu Xiao, Hai-Bo Xue, Xia Li, Chao Chen, Guan-Jun Li, Cheng-Mei Yuan & Ming-Yuan Zhang. (2011) A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia利培酮合并知母皂甙元治疗阴性症状为主的精神分裂症的双盲随机对照研究. Neuroscience Bulletin 27:4, pages 258-268.
Crossref
Crossref
Marita Pruessner, Srividya N. Iyer, Kia Faridi, Ridha Joober & Ashok K. Malla. (2011) Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophrenia Research 129:1, pages 29-35.
Crossref
Crossref
L. Skalli & L. Nicole. (2011) Programmes pour premiers épisodes psychotiques : une revue systématique de la littérature. L'Encéphale 37, pages S66-S76.
Crossref
Crossref
G. K. Murray. (2010) The emerging biology of delusions. Psychological Medicine 41:1, pages 7-13.
Crossref
Crossref
Surendra P. Singh, Vidhi Singh, Nilamadhab Kar & Kelvin Chan. (2018) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. British Journal of Psychiatry 197:3, pages 174-179.
Crossref
Crossref
Jussi Mäkinen, Jouko Miettunen, Erika Jääskeläinen, Juha Veijola, Matti Isohanni & Hannu Koponen. (2010) Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Research 178:1, pages 121-125.
Crossref
Crossref
Steven M. Grauer, Virginia L. Pulito, Rachel L. Navarra, Michele P. Kelly, Cody Kelley, Radka Graf, Barbara Langen, Sheree Logue, Julie Brennan, Lixin Jiang, Erik Charych, Ute Egerland, Feng Liu, Karen L. Marquis, Michael Malamas, Thorsten Hage, Thomas A. Comery & Nicholas J. Brandon. (2009) Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia. Journal of Pharmacology and Experimental Therapeutics 331:2, pages 574-590.
Crossref
Crossref